Peapod Lane Capital LLC Takes Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Peapod Lane Capital LLC purchased a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 108,853 shares of the company’s stock, valued at approximately $836,000. Peapod Lane Capital LLC owned about 0.30% of iTeos Therapeutics at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. nVerses Capital LLC boosted its stake in shares of iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after purchasing an additional 1,700 shares during the period. Point72 DIFC Ltd bought a new stake in iTeos Therapeutics during the 3rd quarter valued at $31,000. China Universal Asset Management Co. Ltd. boosted its position in iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after buying an additional 2,646 shares during the period. Clear Harbor Asset Management LLC bought a new stake in iTeos Therapeutics in the 4th quarter worth $96,000. Finally, Virtu Financial LLC purchased a new position in shares of iTeos Therapeutics in the third quarter valued at about $102,000. 97.16% of the stock is owned by hedge funds and other institutional investors.

iTeos Therapeutics Trading Up 1.5 %

NASDAQ:ITOS opened at $7.29 on Thursday. The company has a 50-day moving average price of $7.69 and a 200-day moving average price of $10.46. The stock has a market cap of $266.30 million, a price-to-earnings ratio of -2.31 and a beta of 1.38. iTeos Therapeutics, Inc. has a 12 month low of $7.06 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.13. Equities analysts forecast that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ITOS. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of iTeos Therapeutics in a report on Thursday, January 16th. Wells Fargo & Company lowered their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Finally, Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research report on Friday, January 10th.

Insider Transactions at iTeos Therapeutics

In other news, CFO Matthew Gall purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the transaction, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at $505,766.17. This trade represents a 8.27 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.50% of the company’s stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.